CMNDNasdaqPharmaceutical PreparationsFiscal year ends October 31

Clearmind Medicine Inc.

Financials through Q3 FY2026, quarter ended Jul 31, 2026

$6.00−0.26 (-4.15%)

Close on Oct 19, 2026

Market cap: $9.49M
P/E (TTM): –
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

No earnings releases found

Clearmind Medicine has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Press releases

Announcements Clearmind Medicine filed with the SEC

Oct 13, 2026, 6:16 AM ET
PRESS RELEASE TITLED: "CLEARMIND: CHARGING ROBOTICS LAUNCHES NEXT-GENERATION AUTOMATED EV-CHARGING TECHNOLOGY FOR ROBOTAXIS AND AUTONOMOUS FLEETS"
EX-99.1 to Form 6-K
Oct 8, 2026, 7:55 AM ET
PRESS RELEASE TITLED: "CLEARMIND ANNOUNCES PATENT PUBLICATION IN JAPAN COVERING TREATMENT FOR NEUROLOGICAL MOVEMENT DISORDER"
EX-99.1 to Form 6-K
Oct 7, 2026, 8:41 AM ET
PRESS RELEASE TITLED: "CLEARMIND ADVANCES DIALOGUE WITH U.S. FEDERAL GOVERNMENT ON PSYCHEDELIC THERAPIES, SUBMITTING RECOMMENDATIONS TO FDA"
EX-99.1 to Form 6-K
Sep 23, 2026, 8:00 AM ET
PRESS RELEASE TITLED: CLEARMIND ENHANCES U.S. IP PRESENCE WITH PUBLICATION OF THREE PATENT APPLICATIONS COVERING LSD, KETAMINE AND IBOGAINE COMBINATIONS
EX-99.1 to Form 6-K
Sep 17, 2026, 4:00 PM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE DELIVERS BRIEFING TO FDA FOLLOWING INVITATION TO HISTORIC PSYCHEDELIC HEARING IN WASHINGTON, D.C."
EX-99.1 to Form 6-K
Sep 14, 2026, 6:08 AM ET
PRESS RELEASE TITLED: "CLEARMIND ENROLLS FIRST PATIENTS WITH ALCOHOL USE DISORDER IN CMND-100 CLINICAL TRIAL"
EX-99.1 to Form 6-K
Sep 10, 2026, 4:05 PM ET
Condensed Interim Consolidated Financial Statements
EX-99.1 to Form 6-K
Sep 10, 2026, 4:05 PM ET
MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED JULY 31, 2026
EX-99.2 to Form 6-K
Sep 8, 2026, 7:43 AM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE RECEIVES YALE IRB APPROVAL, ENABLING PATIENT RECRUITMENT FOR PARTS B AND C OF CMND-100 PHASE I/II TRIAL, FOLLOWING POSITIVE SAFETY RESULTS"
EX-99.1 to Form 6-K
Sep 4, 2026, 7:35 AM ET
Clearmind Medicine Signs Definitive Agreement
EX-99.1 to Form 6-K
Sep 2, 2026, 4:01 PM ET
This Conversion Agreement (this “Agreement”) is entered
EX-99.1 to Form 6-K
Sep 1, 2026, 8:01 AM ET
PRESS RELEASE TITLED: "CLEARMIND REACHES KEY MILESTONE: CMND-100 PHASE IIA UNDERWAY FOR ALCOHOL USE DISORDER TRIAL, ONE-THIRD OF PART C ENROLLED"
EX-99.1 to Form 6-K
Aug 24, 2026, 4:00 PM ET
PRESS RELEASE TITLED: "CLEARMIND ADVANCES MDMA-N-ACYLETHANOLAMINES IP FOR THE TREATMENT OF PTSD AMID RISING U.S. FEDERAL SUPPORT FOR PSYCHEDELIC INNOVATION"
EX-99.1 to Form 6-K
Aug 11, 2026, 4:01 PM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE ANNOUNCES POSITIVE PERMEATION RESULTS FOR INTRANASAL MEAI FORMULATION, SUPPORTING ENHANCED NASAL RETENTION WITHOUT COMPROMISING DRUG DELIVERY"
EX-99.1 to Form 6-K
Aug 6, 2026, 4:00 PM ET
PRESS RELEASE TITLED: "CLEARMIND REACHES KEY CLINICAL TRIAL MILESTONE AS DSMB UNANIMOUSLY CLEARS PROGRESSION IN AUD STUDY"
EX-99.1 to Form 6-K
Aug 3, 2026, 8:12 AM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE SIGNS LETTER OF INTENT TO ACQUIRE 51% MAJORITY STAKE IN EV WIRELESS CHARGING SOLUTIONS FOR AUTOMATED PARKING SYSTEMS COMPANY"
EX-99.1 to Form 6-K
Jul 30, 2026, 4:01 PM ET
PRESS RELEASE TITLED: "CLEARMIND ANNOUNCES POSITIVE SAFETY FINDINGS FOR CMND 100, DEMONSTRATING CONSISTENT TOLERABILITY THROUGHOUT FULL DOSE ESCALATION IN PART A OF ITS FDA-REGULATED CLINICAL TRIAL"
EX-99.1 to Form 6-K
Jul 20, 2026, 4:00 PM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE EXPENDS GLOBAL IP PORTFOLIO WITH HONG KONG PATENT FILING FOR NOVEL PSYCHEDELIC COMPOUNDS; TARGETS MULTI-BILLION-DOLLAR PTSD THERAPEUTICS MARKET"
EX-99.1 to Form 6-K
Jul 17, 2026, 4:01 PM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE COMMENDS FEDERAL MOMENTUM IN ADVANCING PSYCHEDELIC-BASED THERAPIES FOR MENTAL HEALTH AND ADDICTION"
EX-99.1 to Form 6-K
Jul 16, 2026, 1:39 PM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE REPORTS POSITIVE RETENTION RESULTS FOR INTRANASAL FORMULATION OF ITS PSYCHEDELIC-BASED NEUROPLASTOGEN MEAI"
EX-99.1 to Form 6-K
Jul 13, 2026, 4:01 PM ET
PRESS RELEASE TITLED: "CLEARMIND SHARES PROMISING REAL-WORLD INSIGHTS FROM ONGOING CMND-100 FIRST-IN-HUMAN TRIAL"
EX-99.1 to Form 6-K
Jul 10, 2026, 4:00 PM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE RESPONDS TO THE U.S. ADMINISTRATION'S RFI FOR ADDICTION TREATMENT INNOVATIONS AS PART OF THE GREAT AMERICAN RECOVERY INITIATIVE"
EX-99.1 to Form 6-K
Jul 7, 2026, 4:01 PM ET
PRESS RELEASE TITLED: "CLEARMIND REPORTS SUCCESSFUL FORMULATION FEASIBILITY STUDY SUPPORTING POTENTIAL NEW ADDITIONAL ROUTE OF ADMINISTRATION DEVELOPMENT FOR MEAI"
EX-99.1 to Form 6-K
Jun 29, 2026, 8:11 AM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE ADVANCES ITS INNOVATION WITH NEWLY GRANTED U.S. PATENT, ENHANCING GLOBAL PATENT STRENGTH"
EX-99.1 to Form 6-K
Jun 22, 2026, 8:08 AM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE REACHES MAJOR MILESTONE, COMPLETING PART A TREATMENT IN FDA-REGULATED PHASE I/II TRIAL"
EX-99.1 to Form 6-K
Jun 18, 2026, 8:11 AM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE GRANTED U.S. PATENT FOR BINGE BEHAVIOR REGULATORS"
EX-99.1 to Form 6-K
Jun 16, 2026, 7:35 AM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE COMPLETES DOSING FOR PART A OF ITS OF FDA-REGULATED PHASE I/II CLINICAL TRIAL"
EX-99.1 to Form 6-K
Jun 15, 2026, 4:01 PM ET
Condensed Interim Consolidated Financial Statements
EX-99.1 to Form 6-K
Jun 15, 2026, 4:01 PM ET
MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THREE AND SIX MONTHS ENDED APRIL 30, 2026
EX-99.2 to Form 6-K
Jun 12, 2026, 4:01 PM ET
AGREEMENT DATED JUNE 12, 2026 REGARDING ADDITIONAL PURCHASE OF CONVERTIBLE PROMISSORY NOTES
EX-99.1 to Form 6-K
May 29, 2026, 8:35 AM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE ADVANCES GLOBAL INTELLECTUAL PROPERTY PORTFOLIO WITH JAPANESE PATENT FILING FOR INNOVATIVE PSYCHEDELIC- BASED DEPRESSION TREATMENT"
EX-99.1 to Form 6-K
May 26, 2026, 8:30 AM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE ANNOUNCES JOHNS HOPKINS IRB APPROVAL TO ADVANCE CMND-100 PHASE I/II CLINICAL TRIAL TO THE NEXT PARTS"
EX-99.1 to Form 6-K
May 19, 2026, 6:51 AM ET
This Conversion Agreement (this “Agreement”) is entered
EX-99.1 to Form 6-K
May 19, 2026, 6:21 AM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE ANNOUNCES 1-FOR-10 REVERSE SHARE SPLIT"
EX-99.1 to Form 6-K
May 18, 2026, 4:01 PM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE SIGNS AGREEMENT TO EXAMINE MEAI IN COMBINATION AND SEQUENCING WITH TIRZEPATIDE AGAINST BLOCKBUSTER GLP-1 MEDICATIONS"
EX-99.1 to Form 6-K
May 12, 2026, 9:27 AM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE REACHES IMPORTANT CLINICAL MILESTONE: 20 PARTICIPANTS NOW TREATED IN ONGOING PHASE I/IIA TRIAL OF CMND-100 FOR ALCOHOL USE DISORDER"
EX-99.1 to Form 6-K
May 5, 2026, 8:53 AM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE ANNOUNCES FILING OF EUROPEAN PATENT APPLICATION FOR NOVEL PSYCHEDELIC COMPOUNDS FOR THE TREATMENT OF PTSD"
EX-99.1 to Form 6-K
Apr 27, 2026, 7:45 AM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE ANNOUNCES EVALUATION OF ITS PSYCHEDELIC-BASED TREATMENT (MEAI) FOR POTENTIAL FDA BREAKTHROUGH THERAPY DESIGNATION"
EX-99.1 to Form 6-K
Apr 20, 2026, 4:05 PM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE WELCOMES PRESIDENT TRUMPS EXECUTIVE ORDER AS A HISTORIC CATALYST FOR PSYCHEDELIC INNOVATION AND VETERAN MENTAL HEALTH CARE"
EX-99.1 to Form 6-K
Apr 15, 2026, 9:15 AM ET
PRESS RELEASE TITLED: "CLEARMIND MEDICINE ANNOUNCES POSITIVE DATA SAFETY MONITORING BOARD RECOMMENDATION IN ONGOING CMND-100 CLINICAL TRIAL"
EX-99.1 to Form 6-K